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Synopsis for Table of Contents: An oncofertility program, available to newly diagnosed breast 
cancer patients, facilitated discussions about fertility preservation options and increased fertility 
specialist referrals, appointments, and assisted reproduction procedures.  
 
Abstract 
Background and Objectives: Breast cancer treatment can cause premature ovarian failure, yet 
the majority of young cancer patients do not receive adequate education about treatment effects 
before initiating chemotherapy. We studied the impact of an oncofertility program on access to 
fertility preservation. 
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Methods: An oncofertility program was initiated to foster collaboration between oncologists and 
reproductive endocrinologists, and to help increase access to fertility preservation. Documented 
conversations about fertility concerns, specialist referrals, appointments, and fertility 
preservation procedures were compared between breast cancer patients from 2004-2006, before 
oncofertility program initiation, and 2007-2012, after program initiation. The study included 
women < 45, stage 0-III, diagnosed before (n = 278) and after (n = 515) program initiation.  
Results: Demographics for the cohorts were similar. Fertility discussions (p < 0.0001), patients 
interested in maintaining fertility at diagnosis (p = 0.0041), referrals to reproductive 
endocrinologists (p < 0.0001), appointments (p < 0.0001), and fertility preservation procedures 
(p < 0.0183) increased significantly after programmatic implementation.  
Conclusions: An oncofertility program increased discussions about fertility preservation and 
access to assisted reproductive procedures. This program positively impacted compliance with 
national guidelines advising reproductive-age cancer patients to be offered fertility preservation 
counseling as an initial component of the multidisciplinary care plan.  
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INTRODUCTION  
 Among the numerous concerns that a cancer diagnosis imposes on newly diagnosed 
young patients, the risk of infertility is a critical issue [1,2]. Both the patient’s primary 
malignancy and cancer treatment, including surgery, chemotherapy, and radiation, can impact 
fertility temporarily or permanently [3-5]. For young patients seeking fertility preservation, 
referral to a fertility specialist should occur early in the multidisciplinary care plan [6]. Clinician-
driven discussions should be facilitated by providers who are knowledgeable about treatment-
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related fertility risks and fertility preservation options before potentially gonadotoxic therapies 
have been initiated. Accordingly, guidelines established by the American Society of Clinical 
Oncology (ASCO), American Society of Reproductive Medicine (ASRM), and National 
Comprehensive Cancer Network (NCCN) support the pre-treatment counsel of cancer patients 
about fertility preservation and referral to reproductive specialists when indicated [7-9].  
 Despite these guidelines, data shows that 30 to 50% of patients may not receive adequate 
information about fertility risks and preservation practices before initiating cancer treatment 
[10,11]. Female patients are at particular disadvantage with regard to receiving information or 
referrals to fertility specialists, with one survey showing pediatric oncologists routinely referring 
only 23% of female patients for fertility counseling, as opposed to 66% of male patients [12]. 
The barriers to these conversations and referrals are multifactorial: limited time for clinical 
encounters, focus on treatment planning concerns, reluctance to discuss sensitive subjects such as 
sexuality and fertility, inadequate familiarity with fertility preservation techniques, or a lack of 
insight or education associated with initiating conversations about fertility [13].  
 To this end, communication regarding fertility preservation options and appropriate 
referral to a fertility specialist are both critical to quality-of-life during survivorship, and may 
also impact disease outcomes. Affected patients have indicated that the feeling of distress 
associated with the threat to fertility posed by cancer treatment was on par with the distress 
associated with receiving a cancer diagnosis [14,15]. Furthermore, fertility concerns were found 
to negatively impact treatment decision-making, with some breast cancer patients opting to alter 
recommended treatment regimens in attempt to spare fertility [15,16]. Lastly, patients who did 
not pursue fertility preservation options, and subsequently became infertile after cancer 
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treatment, have expressed regret associated with increased anxiety and depression during 
survivorship [17,18]. 
 The scope of fertility preservation for cancer patients is broad, and it can be challenging 
for practitioners to facilitate discussions about fertility amid other critical and life-altering topics. 
A formal oncofertility program can serve multiple functions to help implement this clinical 
practice. With the assistance of dedicated oncofertility care coordinators, a standardized narrative 
for providers can be instituted to initiate the discussion about fertility with patients as part of a 
pre-treatment dialogue, while also building a contextual framework for the available fertility 
preservation resources, and a referral network for providers who can offer fertility preservation 
practices [19,20]. In 2007, Northwestern University implemented an oncofertility program 
encouraging oncologists to address treatment-related infertility, discuss fertility preservation 
options, and refer to reproductive specialists prior to starting potentially gonadotoxic cancer 
treatments.  In the current study, we assessed the impact of this program on access to fertility 
preservation by comparing two cohorts of breast cancer patients diagnosed before and after 
program implementation. We hypothesized that the oncofertility program would help to increase 
provider-driven discussions about fertility, referrals to fertility specialists, and use of fertility 
preservation procedures.  
 
MATERIALS AND METHODS 
 
Patient Selection 
 After institutional review board (IRB) approval, we identified female patients age < 45 
years treated at Northwestern Memorial Hospital’s Lynn Sage Comprehensive Breast Center 
(Chicago, IL) who had been diagnosed with stage 0-III, ER+ and/or PR+ breast cancer between 
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January 1, 2004 and May 31, 2012. The cohorts included premenopausal patients who would be 
undergoing treatment that would impact fertility, including chemotherapy and tamoxifen anti-
hormonal therapy (hormone receptor positive patients).  
An oncofertility program was implemented at Northwestern Hospital in 2007. This 
multifaceted program included outreach and education for medical providers regarding risks of 
cancer treatment-related infertility. A multidisciplinary oncofertility case conference promoted 
cross-disciplinary collaboration between oncologists and reproductive endocrinologists to 
facilitate referrals, establish treatment plans, and expedite procedures for patients undergoing 
cancer treatment. A patient navigator helped patients as they pursued assisted reproductive 
techniques, and were on-call to provide resources and answer patient questions. A 24-hour 
fertility preservation hotline staffed by the patient navigator was available to both patients and 
providers (Figure 1). The program website (myoncofertility.org) compiled helpful educational 
materials and a glossary of terms related to oncofertility and reproductive endocrinology in a 
disease-specific fashion. Additionally, the electronic medical record was modified requiring 
oncology providers to document a discussion about treatment-related infertility with patients 
before the initial intake consultation encounter could be closed.  
Identified patients were separated into a pre-oncofertility program cohort, diagnosed 
between January 1, 2004 and December 31, 2006, and a post-program cohort diagnosed between 
January 1, 2007 and May 31, 2012. We identified 987 women ages 25 - 45 (median age 41) 
treated from 2004 to 2012. Of these patients, 302 were diagnosed from 2004-2006, and 685 were 
diagnosed from 2007-2012. After exclusions, including postmenopausal status at diagnosis, 
recurrent or stage IV disease, no adjuvant therapy information, or adjuvant therapy not 
recommended, the 2004-2006 cohort consisted of 278 patients (Table 1) and the 2007-2012 
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cohort, 515 (Table 2).  
Chart Review 
The patient charts for both study cohorts were reviewed for demographics, disease 
characteristics, and fertility concerns, as documented from new patient intake questionnaires, 
progress notes, operative reports, and pathology reports (Tables 1, 2). To evaluate the impact of 
the oncofertility program, findings from the 2004-2006 pre-program, and 2007-2012 post-
program cohorts were reviewed and compared with regard to number of documented discussions 
with a provider about treatment-related infertility, patients expressing an interest in fertility 
preservation at the time of diagnosis, referrals to a fertility preservation provider, appointments 
with a fertility specialist, and fertility preservation procedures. 
 Information about fertility concerns at diagnosis for patients in the pre-program cohort 
was available when documented in provider notes. After implementation of the formal 
oncofertility program in 2007, prior to closing the initial new patient encounter, a prompt was 
placed into the medical record requiring oncology providers to document a discussion with 
premenopausal patients regarding potential cancer treatment effects on fertility, patient interest in 
fertility preservation, and, if requested, referral for a fertility preservation consultation. 
Information regarding the number of fertility preservation appointments and assisted 
reproductive procedures, including oocyte and embryo cryopreservation, was obtained from the 
patient records.  
Statistical Analyses 
Two-tailed Fisher’s exact test was used to compare the number of discussions about 
treatment effects on fertility, rates of referral to fertility specialists, fertility appointments, and 
assisted reproductive procedures before and after the institution of the oncofertility program. 
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Analyses were conducted using Stata (StataCorp. 2013. Stata Statistical Software: Release 13).  
 
RESULTS 
 Demographic characteristics of the pre-program (Table 1) and post-program (Table 2) 
cohorts were compared. Median age was 41 for both cohorts, with a similar number of patients 
diagnosed before the age of 37 in the pre-program cohort, 25.2%, and the post-program group, 
24.7%. For race and ethnicity, the pre-program cohort was 72.3% white, 10.1% black, 8.6% 
Hispanic, and 4% Asian, and the post-program cohort was 70.5% white, 12.2 black, 7.6% 
Hispanic, and 7.4% Asian, showing the demographic stability of the patient population at the 
study cancer center over time. The majority of patients in both cohorts were married or had a 
domestic partner, 68.7% pre-program, as compared to 64.7% in the post-program cohort. 
Comparisons between the two cohorts regarding disease stage, treatment related issues, smoking 
history, alcohol use, and insurance coverage were also very similar. Regarding parity at the time 
of diagnosis, 33.8% of patients in the pre-program cohort, versus 38.1% of patients in the post-
program cohort, were nulliparous and, correspondingly, a similar proportion of patients in each 
group had one or more children.  
Patient-provider discussions about treatment effects on fertility increased significantly 
after initiation of the oncofertility program, from 9% to 38%, (p < 0.001). Significantly more 
patients in the post-program cohort were documented as having an interest in maintaining 
fertility at the time of diagnosis, increasing from 13.3% to 21.7% (p < 0.0041). Furthermore, 
providers made more referrals to reproductive specialists, (4% versus 28%, p < 0.001), and more 
patients had fertility preservation appointments, (5% versus 18%, p < 0.001) and procedures (4% 
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versus 8%, p < 0.0183) in the post-program cohort when compared to the pre-program cohort 
(Figure 2).  
 
DISCUSSION 
In this study, we found that in a relatively stable patient population over time, an 
oncofertility program promoting discussion about fertility concerns significantly increased the 
rate of documented patient-provider conversations about treatment-related infertility. The 
number of fertility referrals, consultations, and procedures also increased during this timeframe 
(Figure 2). Additionally, after program implementation, which included the initiation of a 
fertility preservation discussion prompt in the electronic medical record, the number of patients 
who expressed interest in preserving their future fertility rose as well. This finding emphasizes 
that although patients value fertility in the context of their cancer treatment, they may not voice 
these concerns unless prompted to do so, secondary to a number of factors including the intense 
nature of a cancer diagnosis, a focus on survival, or a lack of awareness about the risks to fertility 
posed by cancer therapy.  
As cancer therapies become more effective, an increasing number of young patients are 
surviving to look forward to a healthy future, which may include starting a family. Oncofertility 
is an evolving interdisciplinary field seeking to link reproductive medicine with oncology for 
young cancer patients threatened with fertility loss [21]. Often, newly diagnosed young patients 
must make decisions about fertility preservation during a time of great stress and limited time for 
assessment and reflection. Patients benefit from an approach that provides information about 
reproductive options in the context of their cancer treatment, balancing cancer care and 
survivorship with the possibility for fertility preservation [14]. A formal oncofertility program 
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can provide a mechanism to educate oncology caregivers about fertility preservation, while also 
increasing familiarity with evolving reproductive techniques.  
In 2007, the Northwestern oncofertility program initiated a prompt in the electronic 
medical record for oncologists to document fundamental information regarding patient 
education, interest, and referrals for fertility preservation. This intervention provided a reminder 
for clinicians to routinely introduce fertility concerns and options for preservation when 
discussing the trajectory of a new patient’s oncologic care. To further aid providers and patients 
in deciphering this information, a collection of informative oncofertility educational materials 
were generated to translate society guidelines and treatment options into more basic language, 
and these materials were disseminated to caregivers [21]. Some tools used linear, decision tree-
based models to show options facilitating fertility preservation in different scenarios for male 
and female patients, adolescents, or patients at high risk for the development of breast or ovarian 
cancer, serving to aid clinicians in explaining the various options to their patients [19,21]. 
Additionally, a multidisciplinary fertility preservation case conference was instituted to discuss 
treatment planning for newly diagnosed young oncology patients.  
Other critical components of success for the fertility preservation program included the 
use of a dedicated patient navigator to help address fertility preservation-related questions and 
concerns, arrange appropriate referrals and specialist appointments, and to act as a liaison 
between referring providers, reproductive specialists, and the patient. A fertility preservation 
hotline was also available to patients and providers and afforded information and access to the 
patient navigator, typically within 24 hours. Educational materials were also made available on a 
patient-facing website (myoncofertility.org) that defined various oncofertility-related terms and 
provided disease-specific fertility preservation information in multiple languages [19]. The 
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components of this oncofertility program are highlighted in Figure 1 [22]. 
At its inception, the oncofertility program was primarily composed of breast cancer 
patients, as this patient group made up the largest referral population to reproductive specialists. 
As stated, premenopausal breast cancer patients may incur a significant fertility risk associated 
with exposure to chemotherapy and lengthy tamoxifen treatment. As the field of fertility 
preservation has grown, it now includes larger numbers of pediatric patients, adolescents, and 
grown men and women. Furthermore, young patients treated for rheumatologic issues are also 
being referred for fertility preservation. Data is currently being gathered and published to address 
the impact of programmatic implementation for these different patient populations. To this end, 
similar improvements in access to fertility preservation have been observed among male cancer 
patients after the launch of an oncofertility program [23]. 
Opportunities for providers to increase their awareness and understanding of assisted 
reproduction techniques must be routinely facilitated, and several fertility preservation options 
are currently in practice. For female patients, oocyte and embryo cryopreservation are 
components of reproductive medical practice and the standard of therapy for female cancer 
patients pursuing fertility preservation [8,24]. Patients can typically initiate chemotherapy within 
a day or two of oocyte retrieval. The finding that hormonal stimulation can be initiated at any 
point in the menstrual cycle without compromising oocyte yield, a “random-start” protocol, has 
further decreased the time to chemotherapy initiation [25,26]. Additionally, for certain patients, 
increasing flexibility within cancer treatment schedules can help to facilitate fertility preservation 
while balancing appropriate oncologic therapy goals [27]. For breast cancer patients, sequencing 
tamoxifen treatment and fertility interventions, including delaying initiation to attempt 
pregnancy, or a tamoxifien hiatus to pursue pregnancy after initiating therapy, may retain 
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significant therapeutic benefit [1,16,28,29]. The prospective IBCSG POSITIVE trial to examine 
the impact of a tamoxifen treatment hiatus on pregnancy and disease specific outcomes is 
ongoing [30]. Additional research efforts are examining methods to protect gonadal reserve from 
damage by chemotherapy or radiation. As an example, gonadotropin-releasing-hormone 
analogues may help to protect ovarian function from the effects of chemotherapy by inducing 
cellular quiescence [31-33]. For young oncology patients who do not undergo gamete 
preservation, additional options include implementation of donor oocytes/sperm, surrogacy, and 
adoption [1]. 
 
CONCLUSIONS 
 It is critical that oncology practitioners prioritize discussions about fertility preservation 
during the initial consultation with newly diagnosed young oncology patients. This study 
demonstrated the favorable impact of a formal oncofertility program on physician-patient 
communication regarding cancer treatment related effects on fertility. Additionally, comparing 
two cohorts of demographically similar young breast cancer patients over eight years, more 
patients who were treated after oncofertility program implementation expressed an interest in 
maintaining fertility and were then referred to a fertility preservation specialist. The positive 
findings during the study period may have been influenced by the majority of study population 
being married, the growing momentum to incorporate fertility preservation into clinical practice, 
as well as the acceptance of oocyte cryopreservation as standard therapy.  
This being said, while the number of conversations about fertility preservation and 
subsequent actions resulting from these conversations increased for the post-program cohort, 
overall, participation remained modest. The median age of the study population was 41 and 75% 
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of the cohort was > 37, an age when female fertility rates drop significantly. Advanced maternal 
age, which is associated with an increased risk of adverse maternal and fetal events, may have 
independently biased the study findings, reflecting the overall low number of patients 
undergoing fertility preservation procedures. The age distribution of the study cohort reflects 
both the disease epidemiology and our referral population. Simultaneously, pediatric and 
adolescent cancer patient studies also demonstrate the need for increased provider-driven 
education about infertility risk and fertility preservation options [34,35].  
While there is clearly a continued need to improve upon physician-patient engagement in 
oncofertility, factors such as financial issues to cover oncofertility services may also be a 
concern. Currently, in the United States, most insurance carriers do not routinely cover fertility 
preservation costs for cancer patients. This issue is being addressed through agencies including 
the American Medical Association, and on an institutional level through efforts to bundle 
payments for affected patients. Until this financial issue is resolved, future studies will also focus 
on the impact of household income as a marker of financial stability the association with family 
planning and utilization of fertility preservation options.  
 Patients who are rendered infertile post-treatment have expressed considerable anxiety 
and remorse over a lack of information or referral for fertility preservation counseling before the 
initiation of therapy, when fertility preservation options would have been possible [11,17]. To 
this end, providers have a responsibility for educating patients about their treatment options and 
facilitating referrals for patients interested in pursuing fertility preservation techniques [17]. A 
comprehensive, formal oncofertility program including physician collaboration, patient care 
coordination, and consistent documentation provides a structured means of incorporating fertility 
preservation into the multidisciplinary process of oncologic treatment. As studies continue to 
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show the beneficial impact of fertility preservation programs on survivorship, and increasing 
numbers of institutions develop formal programs, it is expected that the oncofertility guidelines 
delineated by ASCO, ASRM, and NCCN will be more widely applied in the clinical setting. 
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Legends 
Figure 1. The interaction between patients, providers, patient navigators, and researchers in an 
oncofertility program. An oncofe tility program should foster collaboration to preserve fertility 
in the setting of cancer care [22]. 
Figure 2. Impact of an oncofertility program on fertility discussions, referrals, and use of fertility 
preservation options. Pre-program 2004-2006 cohort, n = 278. Post-program 2007-2012 cohort, n 
= 515. Discussions about treatment-related infertility increased from 9% to 38%, (p < 0.001). 
Documented interest in maintaining fertility at diagnosis increased from 13.3% to 21.7% (p < 
0.0041). Referrals to reproductive specialists (4% versus 28%, p < 0.001), appointments (5% 
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versus 18%, p < 0.001), and procedures (4% versus 8%, p < 0.0183) all increased in the post-
program cohorts.  
Table 1. Demographics for patients in the pre-oncofertility program cohort from 2004-2006. 
Table 2. Demographics for patients in the post-oncofertility program cohort from 2007-2012. 
 
 
 
 
Table 1. 
 
Table S1. Baseline characteristics of premenopausal patients diagnosed with stage I-III ER+ and/or PR+ breast cancer between 2004-2006, advised to 
take adjuvant tamoxifen  (n = 278).  
Characteristic No. of patients % of total cohort 
Age at diagnosis (years)     
< 37 70 25.2% 
> 37 208 74.8% 
Median age  41   
Race / ethnicity    
White 201 72.3% 
Black 30 10.8% 
Hispanic 24 8.6% 
Asian 11 4.0% 
Other 4 1.4% 
Missing 8 2.9% 
Marital Status     
Unmarried 86 30.9% 
Married, Partnered, Domestic Partner 191 68.7% 
Missing 1 0.4% 
Smoking status    
Current smoker 22 7.9% 
Never smoker 209 75.2% 
Former smoker 44 15.8% 
Missing 3 1.1% 
Alcohol use     
None or < 1 drink per week 130 46.8% 
1-4 drinks per week 101 36.3% 
5-9 drinks per week 34 12.2% 
10 - 19 drinks per week 7 2.5% 
> 19 drinks per week 2 0.7% 
Missing 4 1.4% 
Parity    
Nulliparous 94 33.8% 
Parity > 1 175 62.9% 
Missing 9 3.2% 
Insurance status     
Private insurance 232 83.5% 
Public insurance / uninsured 46 16.5% 
Fertility concerns    
Desires future fertility at diagnosis 37 13.3% 
Does not express fertility concerns at diagnosis 241 86.7% 
Surgery     
Mastectomy 122 43.9% 
Lumpectomy 155 55.8% 
Axillary dissection only 1 0.3% 
Chemotherapy (among patients with stage > 1)    
No 52 21.6.% 
Yes 188 78.0% 
Missing 1 0.4% 
Radiation     
Patient declined 12 4.3% 
Yes 194 69.8% 
XRT not indicated 70 25.2% 
Missing 2 0.7% 
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Stage    
0 37 13.3% 
I 96 34.5% 
II 102 36.7% 
III 43 15.5% 
 
 
 
 
 
 
 
Table 2. 
 
Table 1. Baseline characteristics of premenopausal patients diagnosed with stage I-III ER+ and/or PR+ breast cancer between 2007-2012, advised to take adjuvant 
tamoxifen  (n = 515). 
 
Characteristic No. of patients % of total cohort 
Age at diagnosis (years)   
< 37 127 24.7% 
> 37 388 75.3% 
Median age   
Race / ethnicity   
White 363 70.5% 
Black 63 12.2% 
Hispanic 39 7.6% 
Asian 38 7.4% 
Other 10 1.9% 
Missing 2 0.4% 
Marital Status   
Unmarried 182 35.3% 
Married, Partnered, Domestic Partner 333 64.7% 
Missing 0 0.0% 
Smoking status   
Current smoker 38 7.4% 
Never smoker 365 70.9% 
Former smoker 108 21.0% 
Missing 4 0.8% 
Alcohol use   
None or < 1 drink per week 242 47.0% 
1-4 drinks per week 188 36.5% 
5-9 drinks per week 59 11.5% 
10 - 19 drinks per week 16 3.1% 
> 19 drinks per week 4 0.8% 
Missing 6 1.2% 
Parity   
Nulliparous 196 38.1% 
Parity > 1 312 60.6% 
Missing 7 1.4% 
Insurance status   
Private insurance 445 86.4% 
Public insurance / uninsured 70 13.6% 
Fertility concerns   
Desires future fertility at diagnosis 112 21.7% 
Does not express fertility concerns at diagnosis 403 78.3% 
Surgery   
Mastectomy 272 52.8% 
Lumpectomy 240 46.6% 
Axillary dissection only 1 0.2% 
No surgery 2 0.4% 
Chemotherapy  (among patients w/ stage > 1)   
No 121 29.1% 
Yes 295 70.9% 
Radiation   
Patient declined 36 7.0% 
Yes 355 68.9% 
XRT not indicated 124 24.1% 
Stage   
0 99 19.2% 
I 156 30.3% 
II 183 35.5% 
III 77 15.0% 
 
Au
tho
r M
an
us
cri
pt
 
 
 
 
Oncofertility Figure 1  . 
Au
tho
r M
an
us
cri
pt  
Oncofertility Figure 2  . 
 
